Correction to: Neuropsychopharmacology (2015) 40, 259–267; doi:10.1038/npp.2014.261; published online 22 October 2014
On page 262 (first paragraph under ‘Ketamine’s Abuse Liability: Mu Opioid Receptor Effects’), the references to lambda opioid receptors and lambda antagonists should have been to delta opioid receptors and delta antagonists. The same error appears on page 264 (second paragraph under ‘Novel Drug Development’).
Additional information
The online version of the original article can be found at 10.1038/npp.2014.261
Rights and permissions
About this article
Cite this article
Sanacora, G., Schatzberg, A. Erratum: Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?. Neuropsychopharmacol 40, 1307 (2015). https://doi.org/10.1038/npp.2014.338
Published:
Issue Date:
DOI: https://doi.org/10.1038/npp.2014.338
This article is cited by
-
Experimental medication treatment approaches for depression
Translational Psychiatry (2017)
-
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Drugs (2017)
-
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Nature Medicine (2016)
-
Circumspectives: The Promise of Ketamine
Neuropsychopharmacology (2015)
